Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
62
resultados
Última actualización
12/10/2025 [06:45:00]
Resumen de: WO2025213125A1
The present disclosure provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.
Resumen de: WO2025212259A1
The present disclosure provides methods and compositions for prognosing and treating acute myeloid leukemia. The present disclosure further provides methods and compositions of identifying a prognostic risk comprising detecting the expression level of at least two proteins selected from the group consisting of FGF23, GFAP, IFNL1, IL33, MUC16, OSMR, LCN2, PDGFA, and VSNL1.
Resumen de: WO2025210192A1
The present invention relates to immunosuppressive compounds that deplete coronin 1 levels, in particular to coronin 1 promoter inhibitors. Accordingly, the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, or solvate thereof. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and/or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a pharmaceutical composition comprising the compound of the present invention and a pharmaceutically acceptable carrier.
Resumen de: WO2025210193A1
The present invention relates to immunosuppressive compounds that deplete coronin 1 levels, in particular to coronin 1 promoter inhibitors. Accordingly, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, or solvate thereof. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and/or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a pharmaceutical composition comprising the compound of the present invention and a pharmaceutically acceptable carrier.
Resumen de: WO2025209007A1
The present invention relates to an alkyl diamine-substituted bis-aromatic heterocyclic thioether compound, a preparation thereof, and an application thereof in the preparation of drugs for treating and/or preventing tumors. The structural formula of the compound is as shown in formula (I): the compound has a clear growth-inhibitory effect on various human tumor cells, with good inhibitory activity against breast cancer, liver cancer, pancreatic cancer, kidney cancer, lung cancer, gastric cancer, glioma, ovarian cancer, prostate cancer, esophageal cancer, melanoma, nasopharyngeal carcinoma, colon cancer, cervical cancer, lymphoma, leukemia and other such tumors, wherein the effective IC50 concentration of the compound against tumor cells, such as breast cancer, pancreatic cancer, lung cancer, glioma, ovarian cancer, esophageal cancer, melanoma, colon cancer, cervical cancer, is lower than cisplatin, and experiments show that the compound has broad-spectrum anti-tumor activity. Experiments have further detected that the compound exhibits the effect of degrading PD-L1 proteins, and is a PD-L1 immunomodulator. The present invention provides a new approach for using alkyl diamine-substituted bis-aromatic heterocyclic thioether compounds in the preparation of drugs for treating and/or preventing tumors.
Resumen de: AU2024253099A1
Provided herein are anti-CD19 antibodies and multi-specific binding proteins that bind CD19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific binding proteins, and methods of use of these antibodies or multi-specific binding proteins in treating cancers including relapsing and/or refractory Non-Hodgkins Lymphoma, and cancers that express low levels of CD19.
Resumen de: AU2024255174A1
The present invention provides dosing regimens of bispecific antibodies targeting both CD3 and CD20 when used in the treatment of lymphoma, such as B-cell Non-Hodgkin lymphoma (B-NHL).
Resumen de: AU2024270495A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Resumen de: US2025315946A1
It is disclosed a method processing imaging data of a patient having cancer, for instance lymphoma, comprising:—Providing three-dimensional imaging data of the patient,—computing from said three-dimensional imaging data, at least one two-dimensional Maximum Intensity Projection image. corresponding to the projection of the maximum intensity of the three-dimensional imaging data along one direction onto one plane,—extracting a mask of the MIP image corresponding to cancerous lesions by application of a trained model. Using the extracted mask it is possible to compute one or more cancer prognosis indicators.
Resumen de: US2025314655A1
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
Resumen de: WO2025213122A1
The present disclosure provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.
Resumen de: US2025312327A1
The present invention relates to a composition for co-administration containing a 2,3,5-substituted thiophene compound. The composition has excellent inhibitory activity against cancer cells related to leukemia compared to treatment with the 2,3,5-substituted thiophene compound alone or an anticancer drug alone, and thus may be useful for the prevention, amelioration or treatment of leukemia.
Resumen de: WO2025208227A1
This disclosure relates to methods for identifying Acute Myeloid Leukemia (AML) regeneration enriched cells (RECs) in a patient sample, as well as methods for purifying RECs and for generating RECs, such as for use in an assay for screening therapeutic agents. Also described herein are methods of predicting the prognosis, risk of relapse and/or treatment response in patients with AML, as well as methods for selecting patients with AML for treatment, and methods for treating patients with AML. Further provided are kits for use in the methods described herein.
Resumen de: AU2023406508A1
The present disclosure provides methods of treating acute myeloid leukemia (AML) and methods of determining responsive to AML treatment regimes, the methods comprising identifying the presence or absence of monocytic leukemia stem cells (m-LSCs), including CD70+ m-LSCs, in a sample from a subject.
Resumen de: EP4628071A1
The invention discloses a targeted nanoscale particle, a targeted cell, a preparation method therefor, and use thereof. The targeted nanoscale particle is bound to the outer surface of the targeted cell, and is composed of a plurality of proteins interconnected via a first binding site. The targeted nanoscale particle further comprises a second binding site, and is bound to the outer surface of a target cell via the second binding site. In an exemplary embodiment, the targeted nanoscale particle can promote the interaction between the two types of cells by simultaneously binding to a chimeric antigen receptor T cell and a leukemia cell, thereby promoting the recognition and killing of the leukemia cell by the chimeric antigen receptor T cell. In addition, the internal cavities of the proteins in the targeted nanoscale particle provide space for loading of a chemotherapeutic drug, thus realizing the combination therapy of the chimeric antigen receptor T cell and other therapies while loading the drug.
Resumen de: US2025302939A1
Provided herein is a nucleic acid-based vaccine for human T-cell leukemia virus type 1 (HTLV-1). In some aspects, the vaccine includes a combination of nucleic acid molecules encoding HTLV-1 gag protein and one or both of Type A HTLV-1 Envelope (Env) and Type C HTLV-1 Env. In some aspects, the vaccine includes a combination of nucleic acid molecules encoding HIV-1 gag protein and one or both of Type A HTLV-1 Envelope (Env) and Type C HTLV-1 Env. When administered to a subject, the Env and Gag proteins are expressed in the host and form HTLV-1 virus-like particles (VLPs) that are secreted from cells within the host and elicit an immune response that inhibits HTLV-1 infection.
Resumen de: US2025306026A1
This disclosure relates to the surprising and unexpected finding that the well-known cancer protein, Myeloid Cell Leukemia-1 (MCL-1), binds to and modulates the enzymatic activity of Very Long Chain Acyl CoA Dehydrogenase (VLCAD), thereby regulating fatty acid β-oxidation. This finding is employed in compositions and methods of treating cancer, metabolic diseases, or other conditions characterized by excessive fatty acid β-oxidation by blocking or reducing the energy production of cells (e.g., cancer) through inhibiting the MCL-1/VLCAD interaction and/or directly inhibiting VLCAD enzymatic activity. In addition, the disclosure features methods for identifying such agents that inhibit the interaction between MCL-1 and VLCAD or that inhibit VLCAD enzymatic activity.
Resumen de: US2025305071A1
A method for detecting conjunctival diseases such as conjunctival MALT lymphoma, and an aging biomarker that serves as an indicator of the aging state of a subject are provided. The method for detecting conjunctival diseases comprises a step of comparing a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a healthy person with a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a subject to determine that the ocular surface tissue specimen of the subject has an indication of the conjunctival diseases. The aging biomarker comprises bacterial species which belongs to the Corynebacteriaceae family or the Propionibacteriales family in an ocular surface tissue.
Resumen de: AU2025230668A1
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma. Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma. ep i s c l o s e d a r e m e t h o d s o f t r e a t i n g a s u b j e c t h a v i n g h i g h - r i s k m u l t i p l e m y e l o m a , e p m e t h o d s o f a c h i e v i n g n e g a t i v e m i n i m a l r e s i d u a l d i s e a s e s t a t u s i n a s u b j e c t h a v i n g m u l t i p l e m y e l o m a , a n d m e t h o d s o f p r e d i c t i n g a l i k e l i h o o d o f , o r d e c r e a s i n g a r i s k o f , r e l a p s e a n d o r d i s e a s e p r o g r e s s i o n i n a s u b j e c t h a v i n g m u l t i p l e m y e l o m a
Resumen de: AU2025230686A1
The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents. 5 The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other 5 protective agents. ep h e p r e s e n t i n v e n t i o n p r o v i d e s a v a c c i n e f o r f e l i n e l e u k e m i a v i r u s a n d e p m e t h o d s o f m a k i n g a n d u s i n g t h e v a c c i n e a l o n e , o r i n c o m b i n a t i o n s w i t h o t h e r p r o t e c t i v e a g e n t s
Resumen de: US2025302950A1
Disclosed herein are methods for treating classic Hodgkin lymphoma (cHL) in a subject in need thereof, comprising administering an IL-2 conjugate in combination with an anti-PD-1 antibody or antigen-binding fragment thereof.
Resumen de: US2025304589A1
The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
Resumen de: US2025304705A1
The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: US2025304689A1
The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).
Nº publicación: US2025304697A1 02/10/2025
Solicitante:
ONECHAIN IMNUNOTHERAPEUTICS S L [ES]
FUNDACIO INST DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS [ES]
INST CATALANA DE RECERCA I ESTUDIS AVANCATS [ES]
FUNDACIO INST DINVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL [ES]
ONECHAIN IMNUNOTHERAPEUTICS S.L,
FUNDACI\u00D3 INSTITUT DE RECERCA CONTRA LA LEUC\u00C8MIA JOSEP CARRERAS,
INSTITUCI\u00D3 CATALANA DE RECERCA I ESTUDIS AVAN\u00C7ATS,
FUNDACI\u00D3 INSTITUT D'INVESTIGACI\u00D3 EN CI\u00C8NCIES DE LA SALUT GERMANS TRIAS I PUJOL
Resumen de: US2025304697A1
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. CD1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD1a during ontogeny, confining the risk of on-target/off-tumor toxicity. The present invention provides CD1a-targeting moieties comprising a CD1a-which may be placed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.
BOPI
Sede Electrónica
